GSK's Votrient Will Need To Show Efficacy Outweighs Black Box
This article was originally published in The Pink Sheet Daily
Executive Summary
The sixth drug approved to treat renal cell carcinoma, Votrient wins approval just two weeks after a unanimous endorsement from FDA's Oncologic Drugs Advisory Committee.
You may also be interested in...
FDA Panel Review Of Merck/Ariad’s Sarcoma Drug Could Hinge On Clinical Significance Of Progression-Free Survival Benefit
The Oncologic Drugs Advisory Committee will review two drugs for sarcoma indications on March 20: Merck/Ariad’s Taltorvic (ridaforolimus) and GlaxoSmithKline’s Votrient (pazopanib). With a three-week median PFS advantage in its pivotal trial, ridaforolimus could face the same questions about clinically significant benefit that led to revocation of Avastin’s metastatic breast cancer claim.
Study Design, Feasibility Issues Going To Pediatric Oncology Advisory Subcommittee
Four products to be considered at Nov. 1 meeting, including whether one therapy can advance a cure rate that hasn't changed in 20 years.
Study Design, Feasibility Issues Going To Pediatric Oncology Advisory Subcommittee
Four products to be considered at Nov. 1 meeting, including whether one therapy can advance a cure rate that hasn't changed in 20 years.